TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized Trial of Transcervical Foley Catheter With or Without Oxytocin for Preinduction Cervical Ripening
Brief Summary: The transcervical Foley catheter (TFC) is a proven and effective mode of cervical ripening. It is common practice to use TFC with simultaneous low-dose oxytocin under the assumption that the combination results in a more successful labor induction. Scientific validation of this practice is lacking. We seek to determine if the addition of oxytocin to TFC improves induction success.


Options:
A: Arm Label: Mechanical cervical ripening; Type: EXPERIMENTAL; Interventions: Device: Mechanical cervical ripening | Arm Label: Pharmacological cervical ripening; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pharmacological cervical ripening | Intervention Type: DEVICE; Name: Mechanical cervical ripening; Assigned to Arm(s): Mechanical cervical ripening | Intervention Type: DRUG; Name: Pharmacological cervical ripening; Assigned to Arm(s): Pharmacological cervical ripening
B: Arm Label: weighted bag; Type: ACTIVE_COMPARATOR; Interventions: Other: weighted bag | Arm Label: leg taping; Type: ACTIVE_COMPARATOR; Interventions: Other: leg taping | Intervention Type: OTHER; Name: weighted bag; Assigned to Arm(s): weighted bag | Intervention Type: OTHER; Name: leg taping; Assigned to Arm(s): leg taping
C: Intervention Type: DRUG; Name: low dose oxytocin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: ARD (Atad Ripener Device) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: AID (Atad double balloon Instillation Device) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: folly catheter | Intervention Type: DEVICE; Name: ARD (Atad Ripener Device); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: AID (Atad double balloon Instillation Device); Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: folly catheter; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies
Brief Summary: This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Eligible participants may receive re-treatment with rituximab under a separate protocol WA17531.


Options:
A: Arm Label: Placebo followed by Certolizumab Pegol (CZP); Type: OTHER; Interventions: Other: Placebo, Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Arm Label: Certolizumab Pegol (CZP); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 200 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 400 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP)
B: Arm Label: Placebo Plus Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Other: Placebo | Arm Label: Rituximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: MabThera/Rituxan, Drug: Methotrexate | Intervention Type: DRUG; Name: MabThera/Rituxan; Assigned to Arm(s): Rituximab plus Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo Plus Methotrexate, Rituximab plus Methotrexate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Plus Methotrexate
C: Arm Label: Tocilizumab 162 mg sc; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab 162 mg | Arm Label: Placebo sc; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tocilizumab 162 mg; Assigned to Arm(s): Tocilizumab 162 mg sc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo sc
D: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies
Brief Summary: This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Eligible participants may receive re-treatment with rituximab under a separate protocol WA17531.


Options:
A: Arm Label: Placebo Plus Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Other: Placebo | Arm Label: Rituximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: MabThera/Rituxan, Drug: Methotrexate | Intervention Type: DRUG; Name: MabThera/Rituxan; Assigned to Arm(s): Rituximab plus Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo Plus Methotrexate, Rituximab plus Methotrexate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Plus Methotrexate
B: Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo
C: Arm Label: Sequence 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CP-690,550 or Placebo | Arm Label: Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550 or Placebo; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 2
D: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux (GERD) in Infants Aged 1 to 11 Months, Inclusive
Brief Summary: The purpose of this study is to look at the improvement of a once a day dose of esomeprazole for reducing the signs and symptoms of infants with gastroesophageal reflux disease (GERD). This research study consists of a screening, open-label, and double-blind treatment withdrawal phase. The screening phase ensures the patient eligibility. No study medication is dispensed during the screening phase. During the open-label phase, patients are administered esomeprazole 2.5mg, 5.0mg or 10.0mg based on his/her weight. During the double-blind phase, the patients are administered either his/her open-label dose or placebo. Double-blind means neither the physician, parent, or patient will know if patient is taking esomeprazole or placebo. The patient will have an equal chance of receiving esomeprazole or placebo.


Options:
A: Arm Label: Dexlansoprazole MR 30 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Arm Label: Dexlansoprazole MR 60 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 30 mg QD | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 60 mg QD
B: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo
C: Arm Label: Rabeprazole 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Arm Label: Rabeprazole 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 0.5 mg/kg | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 1.0 mg/kg
D: Intervention Type: DRUG; Name: pantoprazole for approximately 9 weeks.; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux (GERD) in Infants Aged 1 to 11 Months, Inclusive
Brief Summary: The purpose of this study is to look at the improvement of a once a day dose of esomeprazole for reducing the signs and symptoms of infants with gastroesophageal reflux disease (GERD). This research study consists of a screening, open-label, and double-blind treatment withdrawal phase. The screening phase ensures the patient eligibility. No study medication is dispensed during the screening phase. During the open-label phase, patients are administered esomeprazole 2.5mg, 5.0mg or 10.0mg based on his/her weight. During the double-blind phase, the patients are administered either his/her open-label dose or placebo. Double-blind means neither the physician, parent, or patient will know if patient is taking esomeprazole or placebo. The patient will have an equal chance of receiving esomeprazole or placebo.


Options:
A: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo
B: Intervention Type: DRUG; Name: Esomeprazole (Nexium); Assigned to Arm(s): N/A
C: Arm Label: Oral omeprazole; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rectal omeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omeprazole rectally 1mg/kg | Intervention Type: DRUG; Name: Omeprazole rectally 1mg/kg; Assigned to Arm(s): Rectal omeprazole
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid; Assigned to Arm(s): 1, 2, 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Active Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Financial Incentive Group I; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive Group I | Arm Label: Financial Incentives Group II; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive Group II | Intervention Type: BEHAVIORAL; Name: Financial Incentive Group I; Assigned to Arm(s): Financial Incentive Group I | Intervention Type: BEHAVIORAL; Name: Financial Incentive Group II; Assigned to Arm(s): Financial Incentives Group II
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedicine | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Telemedicine | Intervention Type: BEHAVIORAL; Name: Telemedicine; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: Collaborative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: Collaborative Care Treatment; Assigned to Arm(s): Collaborative Care | Intervention Type: BEHAVIORAL; Name: Usual Care Treatment; Assigned to Arm(s): Usual Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Stress Management | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive Stress Management; Assigned to Arm(s): 2
C: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
D: Arm Label: Virtual MBCT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Adapted MBCT | Arm Label: Virtual Health Enhancement Control; Type: EXPERIMENTAL; Interventions: Behavioral: Cardiac Health Enhancement | Intervention Type: BEHAVIORAL; Name: Adapted MBCT; Assigned to Arm(s): Virtual MBCT Intervention | Intervention Type: BEHAVIORAL; Name: Cardiac Health Enhancement; Assigned to Arm(s): Virtual Health Enhancement Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
B: Intervention Type: PROCEDURE; Name: Standard Quality Improvement; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Patient-centered Intervention; Assigned to Arm(s): N/A
C: Arm Label: TCSCT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telepsychiatry-based Culturally Sensitive Collaborative Treatment | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Telepsychiatry-based Culturally Sensitive Collaborative Treatment | Intervention Type: BEHAVIORAL; Name: Telepsychiatry-based Culturally Sensitive Collaborative Treatment; Assigned to Arm(s): TCSCT, Usual Care
D: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Support, management, educational, counselling, follow-up; Assigned to Arm(s): Group A, Group B
B: Arm Label: Community-based nurse care management; Type: EXPERIMENTAL; Interventions: Other: Community-based nurse care management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Community-based nurse care management; Assigned to Arm(s): Community-based nurse care management
C: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
D: Arm Label: CHW Goal Support; Type: EXPERIMENTAL; Interventions: Behavioral: CHW Goal Support | Arm Label: Usual Primary Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHW Goal Support; Assigned to Arm(s): CHW Goal Support

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive diabetes self-management education | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard diabetes education | Intervention Type: BEHAVIORAL; Name: Intensive diabetes self-management education; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard diabetes education; Assigned to Arm(s): Control Group
B: Arm Label: Arm 1: HOPE; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Outcomes through Patient Empowerment (HOPE) | Arm Label: Arm 2: EUC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Healthy Outcomes through Patient Empowerment (HOPE); Assigned to Arm(s): Arm 1: HOPE | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Arm 2: EUC
C: Arm Label: Index group; Type: ACTIVE_COMPARATOR; Interventions: Other: Index group | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Index group; Assigned to Arm(s): Index group
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: regular medical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: The CareWell programme; Type: EXPERIMENTAL; Interventions: Other: The CareWell programme | Intervention Type: OTHER; Name: The CareWell programme; Assigned to Arm(s): The CareWell programme
B: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
C: Arm Label: Community-based nurse care management; Type: EXPERIMENTAL; Interventions: Other: Community-based nurse care management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Community-based nurse care management; Assigned to Arm(s): Community-based nurse care management
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual diabetes and depression care | Arm Label: TeamCare Depression Intervention; Type: EXPERIMENTAL; Interventions: Other: TeamCare Depression Intervention | Intervention Type: OTHER; Name: TeamCare Depression Intervention; Assigned to Arm(s): TeamCare Depression Intervention | Intervention Type: OTHER; Name: Usual diabetes and depression care; Assigned to Arm(s): Usual Care

Answer: B